Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:alternativeTo |
gptkb:Ty21a_vaccine
|
| gptkbp:approvedBy |
adults
children over 2 years |
| gptkbp:ATCCode |
gptkb:J07AP03
|
| gptkbp:boosterInterval |
every 2-3 years
|
| gptkbp:broadcastOn |
single dose
|
| gptkbp:contains |
gptkb:Vi_capsular_polysaccharide_antigen
|
| gptkbp:developedBy |
gptkb:Pasteur_Institute
|
| gptkbp:effect |
about 60-70%
|
| gptkbp:firstLicensed |
1994
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vi polysaccharide vaccine
|
| gptkbp:marketedAs |
gptkb:Sanofi_Pasteur
gptkb:Bharat_Biotech gptkb:Biological_E._Limited gptkb:Biomed_Pvt_Ltd |
| gptkbp:notRecommendedFor |
children under 2 years
|
| gptkbp:routeOfAdministration |
intramuscular
subcutaneous |
| gptkbp:sideEffect |
fever
headache injection site pain malaise |
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:Salmonella_enterica_serovar_Typhi
|
| gptkbp:usedFor |
prevention of typhoid fever
|
| gptkbp:WHOPrequalified |
yes
|
| gptkbp:bfsParent |
gptkb:TCV
|
| gptkbp:bfsLayer |
6
|